Novartis AG: Unternehmensprofil, Finanzberichte & Marktperformance

mehr Informationen über Novartis AG Unternehmen

Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.

Unternehmensinformationen

Unternehmens-codeNVS

Name des UnternehmensNovartis AG

IPO-datumMay 07, 2001

Gegründet am1996

CEODr. Vasant (Vas) Narasimhan, M.D.

Anzahl der mitarbeiter75883

WertpapierartOrdinary Share

GeschäftsjahresendeMay 07

AddresseLichtstrasse 35

StadtBASEL

BörseJohannesburg Stock Exchange

LandSwitzerland

Postleitzahl4056

Telefon41613241111

Websitehttps://www.novartis.com/

Unternehmens-codeNVS

IPO-datumMay 07, 2001

Gegründet am1996

Führungskräfte

Name

Name/Position

Position

Aktienbesitz

Veränderung

Mr. Patrick Horber, M.D.

President - International, Member of the Executive Committee

--

Ms. Ana de Pro Gonzalo

Non-Executive Independent Director

--

Ms. Elizabeth Mcnally

Director

--

Mr. Giovanni Caforio

Chairman of the Board

--

Mr. John D. Young

Non-Executive Independent Director

--

Dr. Robert (Rob) Kowalski

Chief People and Organization Officer, Member of the Executive Committee

--

Dr. Fiona H. Marshall, Ph.D.

President - Biomedical Research, Member of the Executive Committee

--

Dr. Shreeram Aradhye, M.D.

President - Global Drug Development and Chief Medical Officer, Member of the Executive Committee

--

Dr. Simon E. Moroney

Independent Non-Executive Vice Chairman of the Board

--

Ms. Karen L. Hale

Chief Legal Officer, Member of the Executive Committee

--

Name

Name/Position

Position

Aktienbesitz

Veränderung

Mr. Patrick Horber, M.D.

President - International, Member of the Executive Committee

--

Ms. Ana de Pro Gonzalo

Non-Executive Independent Director

--

Ms. Elizabeth Mcnally

Director

--

Mr. Giovanni Caforio

Chairman of the Board

--

Mr. John D. Young

Non-Executive Independent Director

--

Dr. Robert (Rob) Kowalski

Chief People and Organization Officer, Member of the Executive Committee

--

Umsatzaufteilung

Währung: USDUpdate-Zeit: 22 hours ago

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

FY2019

Nach GeschäftsbereichUSD

Name

Umsatz

Anteil

Rest of portfolio

10.07B

20.02%

Cardiovascular, Renal and Metabolism - Entresto

7.82B

15.55%

Immunology - Cosentyx

6.14B

12.20%

Neuroscience - Kesimpta

3.22B

6.41%

Oncology -Kisqali

3.03B

6.03%

Other

20.02B

39.80%

Nach RegionUSD

Name

Umsatz

Anteil

United States

21.15B

42.03%

Other Foreign-

18.51B

36.79%

China

3.89B

7.73%

Germany

3.66B

7.27%

France

1.79B

3.56%

Switzerland

1.31B

2.61%

Nach Geschäftsbereich

Nach Region

Nach GeschäftsbereichUSD

Name

Umsatz

Anteil

Rest of portfolio

10.07B

20.02%

Cardiovascular, Renal and Metabolism - Entresto

7.82B

15.55%

Immunology - Cosentyx

6.14B

12.20%

Neuroscience - Kesimpta

3.22B

6.41%

Oncology -Kisqali

3.03B

6.03%

Other

20.02B

39.80%

Aktionäre

Update-Zeit: Fri, Mar 28

Aktionärsstatistik

Art

Aktionärsstatistik

Aktionäre

Anteil

Dodge & Cox

0.62%

PRIMECAP Management Company

0.56%

Dimensional Fund Advisors, L.P.

0.41%

Loomis, Sayles & Company, L.P.

0.28%

Franklin Mutual Advisers, LLC

0.22%

Other

97.91%

Aktionärsstatistik

Aktionäre

Anteil

Dodge & Cox

0.62%

PRIMECAP Management Company

0.56%

Dimensional Fund Advisors, L.P.

0.41%

Loomis, Sayles & Company, L.P.

0.28%

Franklin Mutual Advisers, LLC

0.22%

Other

97.91%

Art

Aktionäre

Anteil

Investment Advisor

3.26%

Investment Advisor/Hedge Fund

2.64%

Research Firm

0.37%

Hedge Fund

0.28%

Bank and Trust

0.12%

Pension Fund

0.03%

Family Office

0.01%

Other

93.29%

Institutionelle Beteiligung

Update-Zeit: Thu, Feb 20

Berichtszeitraum

Anzahl der Institutionen

Gehaltenen Aktien

Anteil

Veränderung

2025Q1

1881

133.48M

6.75%

-9.09M

2024Q4

1926

134.00M

6.78%

-9.24M

2024Q3

1858

134.89M

6.74%

-11.71M

2024Q2

1840

139.20M

6.87%

-9.16M

2024Q1

1808

141.30M

6.92%

-7.93M

2023Q4

1811

141.99M

6.94%

-15.97M

2023Q3

1775

150.92M

7.33%

-7.18M

2023Q2

1759

150.74M

7.28%

-24.15M

2023Q1

1762

167.49M

7.98%

-13.01M

2022Q4

1782

173.67M

8.19%

-17.15M

Aktionärsaktivitäten

Name

Gehaltenen Aktien

Anteil

Veränderung

Änderung%

Datum

Dodge & Cox

12.21M

0.62%

-7.21K

-0.06%

Dec 31, 2024

PRIMECAP Management Company

11.03M

0.56%

-983.02K

-8.19%

Dec 31, 2024

Dimensional Fund Advisors, L.P.

8.18M

0.41%

+90.82K

+1.12%

Dec 31, 2024

Loomis, Sayles & Company, L.P.

5.58M

0.28%

-192.68K

-3.34%

Dec 31, 2024

Franklin Mutual Advisers, LLC

4.26M

0.22%

-16.98K

-0.40%

Dec 31, 2024

Wellington Management Company, LLP

3.65M

0.18%

-351.31K

-8.78%

Dec 31, 2024

Morgan Stanley Smith Barney LLC

3.59M

0.18%

-52.88K

-1.45%

Dec 31, 2024

Parametric Portfolio Associates LLC

2.98M

0.15%

-86.17K

-2.81%

Dec 31, 2024

Managed Account Advisors LLC

2.95M

0.15%

-214.17K

-6.76%

Dec 31, 2024

Renaissance Technologies LLC

2.67M

0.14%

+368.17K

+16.00%

Dec 31, 2024

Verbundene ETFs

Update-Zeit: Wed, Apr 2

Name

Anteil

VanEck Pharmaceutical ETF

5.29%

Cullen Enhanced Equity Income ETF

4.16%

Invesco International Dividend Achievers ETF

2.69%

Amplify International Enhanced Dividend Income ETF

2.67%

Altrius Global Dividend ETF

2.35%

SGI Enhanced Global Income ETF

2.07%

Pacer Global Cash Cows Dividend ETF

2.06%

Abacus FCF International Leaders ETF

1.9%

SP Funds S&P World (ex-US) ETF

1.78%

The Opal International Dividend Income ETF

1.74%

VanEck Pharmaceutical ETF

Anteil5.29%

Cullen Enhanced Equity Income ETF

Anteil4.16%

Invesco International Dividend Achievers ETF

Anteil2.69%

Amplify International Enhanced Dividend Income ETF

Anteil2.67%

Altrius Global Dividend ETF

Anteil2.35%

SGI Enhanced Global Income ETF

Anteil2.07%

Pacer Global Cash Cows Dividend ETF

Anteil2.06%

Abacus FCF International Leaders ETF

Anteil1.9%

SP Funds S&P World (ex-US) ETF

Anteil1.78%

The Opal International Dividend Income ETF

Anteil1.74%

Dividende

In den vergangenen 5 Jahren wurden insgesamt 36.74B USD an Dividenden ausgeschüttet.

Datum

Dividende

Stichtag für die Aktienregistrierung

Zahltag

Ex-Dividendentag

Feb 20, 2025

NVS.NB Approximate final Cash Dividend of gross USD 3.869541 going ex on Mar 12, 2025

Mar 12, 2025

May 01, 2025

Mar 12, 2025

Feb 12, 2024

NVS.NB Final Cash Dividend of gross USD 3.739544 paid on Apr 19, 2024 going ex on Mar 07, 2024

Mar 08, 2024

Apr 19, 2024

Mar 07, 2024

Feb 02, 2023

NVS.NB Final Cash Dividend of gross USD 3.498699 paid on Mar 20, 2023 going ex on Mar 09, 2023

Mar 10, 2023

Mar 20, 2023

Mar 09, 2023

Feb 04, 2022

NVS.NB Final Cash Dividend of gross USD 3.32525 paid on Mar 17, 2022 going ex on Mar 08, 2022

Mar 09, 2022

Mar 17, 2022

Mar 08, 2022

Jan 26, 2021

NVS.NB Final Cash Dividend of gross USD 3.199072 paid on Mar 15, 2021 going ex on Mar 04, 2021

Mar 05, 2021

Mar 15, 2021

Mar 04, 2021

Jan 31, 2020

NVS.NB Final Cash Dividend of gross USD 3.087366 paid on Mar 12, 2020 going ex on Mar 03, 2020

Mar 04, 2020

Mar 12, 2020

Mar 03, 2020

Aktien-Split

Datum

Art

Verhältnis

Keine Daten

Datum

Art

Verhältnis

Keine Daten

Novartis AG

112.720USD

Novartis AG

112.720

Übersicht

Unternehmen